Compare Stocks: IMTX, ABCL, EWTX, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$13.74 -1.2%	$10.65	$2.74 ▼ $15.02	$4.26B	1.41	4.65 million shs	3.70 million shs
EWTX Edgewise Therapeutics	$41.40 +2.3%	$42.92	$14.25 ▼ $48.51	$4.40B	0.35	1.64 million shs	1.43 million shs
IMTX Immatics	$7.59 -10.1%	$9.04	$7.40 ▼ $12.41	$1.15B	1.36	703,809 shs	1.26 million shs
TNGX Tango Therapeutics	$23.24 -4.9%	$24.85	$6.69 ▼ $34.39	$4.12B	1.17	3.04 million shs	5.25 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-1.22%	+8.19%	+20.95%	+69.42%	+130.54%
EWTX Edgewise Therapeutics	+2.27%	+5.24%	-1.38%	+4.65%	+168.13%
IMTX Immatics	-10.07%	-9.32%	-20.11%	-23.72%	-15.67%
TNGX Tango Therapeutics	-4.95%	-6.74%	+4.12%	-21.11%	+191.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$13.74 -1.2%	$10.65	$2.74 ▼ $15.02	$4.26B	1.41	4.65 million shs	3.70 million shs
EWTX Edgewise Therapeutics	$41.40 +2.3%	$42.92	$14.25 ▼ $48.51	$4.40B	0.35	1.64 million shs	1.43 million shs
IMTX Immatics	$7.59 -10.1%	$9.04	$7.40 ▼ $12.41	$1.15B	1.36	703,809 shs	1.26 million shs
TNGX Tango Therapeutics	$23.24 -4.9%	$24.85	$6.69 ▼ $34.39	$4.12B	1.17	3.04 million shs	5.25 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-1.22%	+8.19%	+20.95%	+69.42%	+130.54%
EWTX Edgewise Therapeutics	+2.27%	+5.24%	-1.38%	+4.65%	+168.13%
IMTX Immatics	-10.07%	-9.32%	-20.11%	-23.72%	-15.67%
TNGX Tango Therapeutics	-4.95%	-6.74%	+4.12%	-21.11%	+191.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$13.38	-2.66% Downside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$51.33	23.99% Upside
IMTX Immatics	2.63	Moderate Buy	$20.60	171.41% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	87.01% Upside

Current Analyst Ratings Breakdown

Latest IMTX, ABCL, EWTX, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	ABCL AbCellera Biologics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
9/24/2026	ABCL AbCellera Biologics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00
9/21/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $57.00
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	EWTX Edgewise Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$32.00 ➝ $36.00
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	56.07	N/A	N/A	$3.23 per share	4.25
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
IMTX Immatics	$54.60M	19.00	N/A	N/A	$4.09 per share	1.86
TNGX Tango Therapeutics	$62.38M	62.82	N/A	N/A	$2.57 per share	9.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/9/2026 (Confirmed)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest IMTX, ABCL, EWTX, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
EWTX Edgewise Therapeutics	N/A	16.24	16.24
IMTX Immatics	N/A	7.54	7.54
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
EWTX Edgewise Therapeutics	N/A
IMTX Immatics	64.41%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
EWTX Edgewise Therapeutics	21.30%
IMTX Immatics	3.30%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
IMTX Immatics	704	136.69 million	132.18 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

IMTX, ABCL, EWTX, and TNGX Headlines

Recent News About These Companies

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.4% - Here's Why

October 2 at 2:39 PM | marketbeat.com

Head-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) versus Tango Therapeutics (NASDAQ:TNGX)

September 30 at 5:14 AM | americanbankingnews.com

Comparing Tango Therapeutics (NASDAQ:TNGX) and Syndax Pharmaceuticals (NASDAQ:SNDX)

September 28, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (TNGX)

September 27, 2026 | finance.yahoo.com

Il principale responsabile contabile di Tango Therapeutics vende azioni per $198k

September 25, 2026 | it.investing.com

Tango Therapeutics (NASDAQ:TNGX) Insider Jessica Newcomb Sells 8,200 Shares of Stock

September 25, 2026 | insidertrades.com

600,834 Shares of Tango Therapeutics, Inc. $TNGX Purchased by Bank of America Corp DE

September 25, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Jessica Newcomb Sells 8,200 Shares

September 24, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Up 6% - What's Next?

September 24, 2026 | americanbankingnews.com

Tango Therapeutics (NASDAQ:TNGX) Trading 6% Higher - Here's Why

September 22, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 22, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from Analysts

September 22, 2026 | marketbeat.com

Squarepoint Ops LLC Sells 155,357 Shares of Tango Therapeutics, Inc. $TNGX

September 19, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.6% - Here's What Happened

September 18, 2026 | marketbeat.com

Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

September 18, 2026 | marketbeat.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

September 10, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 10, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.5% - Still a Buy?

September 9, 2026 | marketbeat.com

Legal & General Group Plc Makes New $2.68 Million Investment in Tango Therapeutics, Inc. $TNGX

September 6, 2026 | marketbeat.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, ABCL, EWTX, and TNGX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$13.74 -0.17 (-1.22%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$13.78 +0.04 (+0.25%)

As of 10/2/2026 07:56 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Edgewise Therapeutics NASDAQ:EWTX

$41.40 +0.92 (+2.27%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$41.40 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Immatics NASDAQ:IMTX

$7.59 -0.85 (-10.07%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.59 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Tango Therapeutics NASDAQ:TNGX

$23.24 -1.21 (-4.95%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$22.92 -0.31 (-1.36%)

As of 10/2/2026 07:44 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMTX, ABCL, EWTX, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMTX, ABCL, EWTX, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMTX, ABCL, EWTX, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, ABCL, EWTX, and TNGX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Edgewise Therapeutics NASDAQ:EWTX

Immatics NASDAQ:IMTX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMTX, ABCL, EWTX, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMTX, ABCL, EWTX, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMTX, ABCL, EWTX, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, ABCL, EWTX, and TNGX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Edgewise Therapeutics NASDAQ:EWTX

Immatics NASDAQ:IMTX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools